Dan Weinrieb, the Head of Strategic Partnerships at Jukebox Health, discusses aging at home and the federal policies that need to be improved in order to support it; and Stealth BioTherapeutics is considering giving up on getting full FDA approval of their therapy for Barth syndrome which would be detrimental to all who have the condition. 

Jukebox Health Website

STAT News Article: ‘We’ve exhausted all avenues’: A small biotech may give up on its ultra-rare disease drug over frustration with FDA